Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1

Conditions

Recurrence 5Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Multiple Myeloma 3Primary Myelofibrosis 2Oligodendroglioma 2Neuroblastoma 2Myeloproliferative Disorders 2Lymphoma 2Leukemia, Myeloid, Acute 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Thrombocytosis 1Thrombocythemia, Essential 1Sezary Syndrome 1Rhabdomyosarcoma 1Polycythemia Vera 1Polycythemia 1Osteosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Neuroepithelial 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 209fludarabine phosphate 184Azacitidine 159fludarabine 142Busulfan 138Tacrolimus 119Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 106Peripheral Blood Stem Cell Transplantation 98Antilymphocyte Serum 97Melphalan 90Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 42Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Injections 27Biopsy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic Syndromes × imetelstat × Clear all
NCT05583552 2026-05-12

IMpress

GCP-Service International West GmbH

Phase 2 Active not recruiting
46 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting
289 enrolled 35 charts 1 FDA
Myeloid

Myelodysplastic Syndromes, Recurrence

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Geron Corporation

Phase 2 Completed
80 enrolled 31 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡